Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.47 |
| ▸ | PIM1 | P11309 | 11/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 9/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20190843 | 0.88 | SCN5A (0.61) | CYP1A2SCN5APIM1PIM2FLT3 | |
| SCHEMBL20191052 | 0.84 | SCN5A (0.50) | SCN5APIM1PIM2MAOAMAOB | |
| SCHEMBL20190776 | 0.84 | SCN5A (0.58) | CYP1A2SCN5APIM1PIM2FLT3 | |
| SCHEMBL20190267 | 0.80 | SCN5A (0.59) | CYP1A2SCN5AMAOAMAOB | |
| SCHEMBL20190535 | 0.77 | SCN5A (0.73) | CYP1A2SCN5APIM1PIM2FLT3 | |
| SCHEMBL23572407 | 0.72 | SCN5A (0.64) | CYP1A2SCN5APIM1PIM2FLT3 | |
| SCHEMBL20190080 | 0.72 | SCN5A (0.65) | SCN5APIM1PIM2MAOAMAOB | |
| SCHEMBL20189286 | 0.71 | SCN5A (0.67) | CYP1A2SCN5APIM1PIM2FLT3 | |
| SCHEMBL24024509 | 0.71 | CYP1A2 (0.48) | CYP1A2PIM1PIM2MAOAMAOB | |
| SCHEMBL20190540 | 0.70 | CYP1A2 (0.70) | CYP1A2SCN5APIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885PIM1 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.